Rheumatology Search
Rheumatology Rheumatology
gout
GOUT
Gout is a condition that resulted from deposition of monosodium urate crystals in various tissues (eg joints, connective tissue, kidney).
The patient experiences acute and chronic arthritis, soft tissue inflammation, tophus formation, gouty nephropathy and nephrolithiasis.
Primary hyperuricemia occurs when uric acid saturation arises without coexisting diseases or drugs that alter uric acid production or excretion, while secondary hyperuricemia is a condition where excessive uric acid production or diminished renal clearance occurs as a result of a disease, drug, dietary product or toxin. 

Gout Signs and Symptoms

Definition

  • Gout is a condition wherein there is increased urate in the body, also called hyperuricemia, that leads to deposition of monosodium urate monohydrate crystals in various tissues (eg joints, connective tissue, kidney)

Pathophysiology

  • Hyperuricemia is a necessary precondition for the development of monosodium urate monohydrate crystal deposition but this has to be distinguished from gout, the clinical syndrome
  • Results in acute and chronic inflammation associated with changes in articular and periarticular structures

Epidemiology

  • It is the most common inflammatory arthritis in men
  • In US and Europe, the estimated prevalence of gout is 3% of adults
  • Prevalence of gout in the Asia-Pacific region varies
    • Ethnic groups in China and Malaysia (eg Malays, Tamils) were found to have higher uric levels as compared to the Japanese and Thai
    • Taiwan is one of the countries in the world with highest prevalence of gout

Risk Factors

Risk factors for gout and associated comorbidity should be assessed

Risk Factors Associated with Gout

  • Hyperuricemia
    • Single most important risk factor for developing gout
  • Male sex
  • Menopausal women
  • Age
  • Purine-rich diet (eg meat, seafood)
  • Alcohol intake
  • Drug use (eg diuretics, low-dose Aspirin, Ciclosporin)
  • Lead exposure
  • Obesity
  • Renal insufficiency

Metabolic Abnormalities/Comorbidities Associated with Gout

  • Hypertension
  • Obesity
  • Dyslipidemia
  • Hyperglycemia and insulin resistance
  • Coronary artery disease
  • Type 2 diabetes mellitus
  • Renal insufficiency
  • Metabolic syndrome
  • Kidney stone
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Alzheimer’s disease prevention: Can antidepressants lend a hand?
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.